Oppenheimer Asset Management Inc. Sells 1,890 Shares of Grifols, S.A. (NASDAQ:GRFS)

Oppenheimer Asset Management Inc. lessened its position in Grifols, S.A. (NASDAQ:GRFSFree Report) by 4.9% in the 3rd quarter, Holdings Channel reports. The firm owned 36,813 shares of the biotechnology company’s stock after selling 1,890 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Grifols were worth $336,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of GRFS. Captrust Financial Advisors grew its holdings in shares of Grifols by 153.5% during the second quarter. Captrust Financial Advisors now owns 2,086 shares of the biotechnology company’s stock worth $25,000 after buying an additional 1,263 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Grifols by 106.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,132 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,618 shares in the last quarter. Amundi grew its holdings in shares of Grifols by 2,512.9% in the 4th quarter. Amundi now owns 3,632 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 3,493 shares in the last quarter. Signaturefd LLC grew its holdings in shares of Grifols by 59.2% in the 2nd quarter. Signaturefd LLC now owns 4,222 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 1,570 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Grifols by 71.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,062 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 3,350 shares in the last quarter. Institutional investors own 16.42% of the company’s stock.

Grifols Stock Up 1.7 %

GRFS stock opened at $8.28 on Friday. The company has a quick ratio of 0.75, a current ratio of 2.48 and a debt-to-equity ratio of 1.20. The company has a fifty day moving average price of $9.24 and a two-hundred day moving average price of $9.31. Grifols, S.A. has a one year low of $6.35 and a one year high of $12.15.

Analyst Ratings Changes

Separately, JPMorgan Chase & Co. raised their price objective on Grifols from $10.00 to $10.50 and gave the company a “neutral” rating in a report on Tuesday, December 5th.

Check Out Our Latest Research Report on Grifols

Grifols Company Profile

(Free Report)

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product.

Featured Stories

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFSFree Report).

Institutional Ownership by Quarter for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.